Experimental Drug Extends Life for Advanced Gastric Cancer Patients

A clinical trial has shown that an experimental drug developed by AstraZeneca significantly extends the lives of patients with advanced gastric cancer. The trial, presented at the European Society for Medical Oncology (ESMO) conference in Madrid, revealed that patients receiving the drug lived an average of ten months, compared to five months for those undergoing standard chemotherapy.

The drug, known as sonic hedgehog inhibitor, is part of a class of treatments that combine antibodies with anti-cancer agents to target specific cells. The results indicated a 53% relative reduction in the risk of death compared to patients who received standard chemotherapy. The study included 532 patients who had previously undergone at least two treatments, with a requirement that a specific protein, Claudin 18.2, be present in at least 25% of their cancer cells.

Susan Galbraith, Executive Vice President of Oncology and Hematology Research and Development at AstraZeneca, highlighted the clinical significance of extending the average survival by five months for patients with difficult-to-treat conditions. The threshold of 25% for the presence of Claudin 18.2 in cancer cells allows for a broader eligibility for the treatment compared to higher thresholds.

While the trial did not meet all its primary objectives, particularly in terms of progression-free survival, it did show a notable improvement in overall survival. The median duration of the study was not specified, but the overall survival benefit was considered clinically significant.

The drug's development represents a potential advancement in targeted therapies for gastric cancer, a disease that often has limited treatment options once it progresses to advanced stages.